Anastrozole is the generic name and the trade name of anastrozole is Arimidex. This medication is used in the treatment of carcinoma of the breast in postmenopausal women, especially breast carcinoma that is hormone receptor-positive and has failed to tamoxifen treatment. Anastrozole is manufactured by AstraZeneca Pharmaceuticals and belongs to a class of drugs referred to as aromatase inhibitors. The active ingredient of Anastrozole is anastrozole and the inactive ingredients include: Lactose. Magnesium stearate. Hydroxypropylmethylcellulose. Polyethylene glycol. Povidone. Sodium starch glycolate. Titanium dioxide.

Anastrozole (INN, trade name: Arimidex) is a drug indicated in the treatment of breast cancer in post-menopaUSAl women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It has the effect of decreasing the amount of estrogen that the body makes.

Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogen.

The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial represents a long-term follow-up study of 9366 women with localized breast cancer who received either anastrozole, tamoxifen, or both. After more than 5 years the group that received anastrozole had significantly better clinical results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopaUSAl women with localized breast cancer that is estrogen receptor positive.